News stories about Baxter International (NYSE:BAX) have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 6,000 blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Baxter International earned a news sentiment score of -1.00 on their scale. InfoTrie also gave news articles about the medical instruments supplier an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have effected Baxter International’s ranking:
- Baxter Shareholders: January 24, 2020 Filing Deadline in Class Action – Contact Lieff Cabraser (finance.yahoo.com)
- CLASS ACTION UPDATE for SEE, UA and BAX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (finance.yahoo.com)
- Somewhat Negative Press Coverage Extremely Likely to Affect Baxter International (NYSE:BAX) Stock Price (americanbankingnews.com)
- BAXTER LOSS ALERT: ROSEN LAW FIRM Reminds Baxter International Inc. Investors of Important January 24th Deadline in Securities Class Action (prnewswire.com)
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baxter International Inc. – BAX (finance.yahoo.com)
Several equities analysts have commented on the company. JPMorgan Chase & Co. set a $94.00 price objective on Baxter International and gave the company a “buy” rating in a research report on Tuesday, October 8th. ValuEngine lowered Baxter International from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Piper Jaffray Companies reissued a “buy” rating on shares of Baxter International in a research report on Tuesday, September 10th. Finally, Deutsche Bank assumed coverage on Baxter International in a research report on Monday, October 21st. They set a “buy” rating and a $109.00 price objective for the company. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $89.77.
The business also recently declared a quarterly dividend, which will be paid on Thursday, January 2nd. Stockholders of record on Friday, December 6th will be given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 1.07%. The ex-dividend date of this dividend is Thursday, December 5th. Baxter International’s dividend payout ratio is presently 28.85%.
In other news, SVP Andrew Frye sold 3,332 shares of Baxter International stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $88.00, for a total value of $293,216.00. Following the completion of the transaction, the senior vice president now owns 16,391 shares of the company’s stock, valued at approximately $1,442,408. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.70% of the stock is owned by insiders.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Recommended Story: Forex
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.